Table 1 Selected input values used in the base-case analysis
Parameter | Value | Reference | |
|---|---|---|---|
Demographic parameters | Males | Females | [28] |
Population size | 61,765,503 | 65,167,269 | |
Birth rate (births/year) | 780,581 | 723,233 | |
Mean number of sexual partners per year by sex and age | |||
13–14 | 1.28 | 1.18 | |
15–17 | 1.08 | 1.09 | |
18–24 | 1.10 | 1.08 | |
25–34 | 1.70 | 1.13 | |
35–44 | 1.72 | 1.05 | |
≥ 45 | 1.17 | 1.04 | |
Percent of the population in each sexual activity categories | [29] | ||
Low (mean number of sexual partners per year: 0–1) | 76.7 | 89.1 | |
Medium (mean number of sexual partners per year: 2–4) | 19.0 | 9.5 | |
High (mean number of sexual partners per year: 5+) | 4.2 | 1.3 | |
Cost of screening, diagnosis, and treatment (2020 ¥, single outpatient/inpatient cost) | [30] | ||
Cervical screening and visit | 3730 | ||
Coloscopy | 5100 | ||
Biopsy | 7000 | ||
Episode of CIN 1 | 76,000 | ||
Episode of CIN 2 or worse | 276,400 | ||
Episode of VaIN 1 | 76,000.0 | ||
Episode of VaIN 2 or worse | 533,700.0 | ||
Case of cervical cancer | |||
Localized | 2,181,900 | ||
Regional | 2,914,300 | ||
Distant | 4,020,800 | ||
Case of vaginal cancer | |||
Localized | 991,400 | ||
Regional | 1,823,400 | ||
Distant | 1,977,400 | ||
Case of vulvar cancer | |||
Localized | 818,500 | ||
Regional | 1,694,800 | ||
Distant | 1,847,200 | ||
Case of penile cancer | |||
Localized | 647,000 | ||
Regional | 1,165,000 | ||
Distant | 1,249,600 | ||
Case of anal cancer | Males | Females | |
Localized | 1,183,000 | 1,183,000 | |
Regional | 1,809,200 | 1,809,200 | |
Distant | 2,659,300 | 2,659,300 | |
Case of oropharyngeal cancer | |||
Localized | 1,169,110 | 1,169,110 | |
Regional | 3,695,570 | 3,695,570 | |
Distant | 5,794,276 | 5,794,276 | |
Case of condyloma acuminatum (anogenital warts) | 11,246 | 11,356 | |
Case of recurrent respiratory papillomatosis | 1,144,296 | 1,144,296 | |
Cost of vaccination (2020 ¥) | |||
3-dose series per dose, 4vHPV | 12,000 | ||
3-dose series per dose, 9vHPV | 20,000 | ||
Administration fee per dose | 3718 | ||
Discount rate per year (%): future costs and effectiveness | 2 | ||